11.01.22 -- Making ePRO and eConsent Easier for Participants and Sites

Many clinical trials face initial hurdles simply due to a complex informed consent process. The benefits of eConsent are multifaceted. In this blog post, explore these advantages as they relate to participants, sites, and sponsors/CROs.

Improving participant retention and mitigating high study costs can be difficult for sponsors, CROs, and sites to achieve at scale. However, the informed consent process is an aspect that can be enhanced at a broader trial level by using eConsent to ultimately retain more participants.

eConsent can have a positive impact on participant retention, but that is only part of the challenge when it comes to meeting participant needs in a clinical trial. In this article, discover the ways informed consent can continue to evolve.

During the height of the COVID-19 pandemic, clinical trial sites appeared to face an existential threat as the industry discussed “siteless” decentralized trials. Delve into the adoption of new clinical trial technology and focus on how sponsors can support sites as they select and implement technologies.

Find out how the Digital Medicine Society (DiMe), an interdisciplinary professional society for digital medicine, was able to deploy an eConsent module in less than two weeks to support its remote study to assess nocturnal scratching as an endpoint for patients with atopic dermatitis.

What makes a clinical trials software provider a good fit? How do you make the decision to use a particular electronic data capture (EDC) system or electronic patient reported outcome (ePRO) solution? These are important questions, and the answers are different for every sponsor and contract research organization (CRO).